Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologically or histologically diagnosed with multiple myeloma stage II/III~* Participants without preceding cytostatic (tending to retard cellular activity and multiplication) treatment (pretreatment with radiation or dexamethasone is allowed)~* Agree to use one of the contraception methods as defined in the protocol~* Karnofsky performance status 60 percent or more~* Adequate laboratory test values~Exclusion Criteria:~* Non-secretory multiple myeloma~* Estimated life expectancy less than 3 months~* History of cancer (except basal cell carcinoma) in the last 5 years~* Peripheral neuropathy (disorder of the peripheral nerves) grade 2 or more~* Positive human immunodeficiency virus test and active hepatitis B and/or hepatitis C~* Pregnant or breast-feeding female participants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide + Bortezomib + Dexamethasone (Type: EXPERIMENTAL): Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).